Peer Review reports
From: Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
| Original Submission | ||
|---|---|---|
| 5 Apr 2022 | Submitted | Original manuscript |
| 23 Apr 2022 | Reviewed | Reviewer Report |
| 4 May 2022 | Reviewed | Reviewer Report - Mohammad Ahmad al-Shatouri |
| 26 May 2022 | Author responded | Author comments - Lanlan Pang |
| Resubmission - Version 2 | ||
| 26 May 2022 | Submitted | Manuscript version 2 |
| 6 Jul 2022 | Reviewed | Reviewer Report - Kazuhiro Araki |
| 28 Nov 2022 | Reviewed | Reviewer Report |
| 9 Dec 2022 | Author responded | Author comments - Lanlan Pang |
| Resubmission - Version 3 | ||
| 9 Dec 2022 | Submitted | Manuscript version 3 |
| Publishing | ||
| 12 Dec 2022 | Editorially accepted | |
| 21 Jan 2023 | Article published | 10.1186/s12885-022-10446-1 |
You can find further information about peer review here.